Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors

Article Abstract:

Recombinant blood coagulant factor VIII appears to be an effective, well-tolerated treatment for patients with hemophilia A. Use of plasma-derived clotting-factor in hemophiliacs risks the transmission of blood-borne viral diseases. Recombinant DNA-derived clotting-factor, however, contains no virus and is thus potentially advantageous to hemophiliacs. Recombinant factor VIII was administered at least once to 95 previously untreated infants and children with hemophilia A. The concentrate was given either for spontaneous or traumatic bleeding or for surgery, and all patients responded well to treatment. Only three patients reported adverse reactions to the recombinant factor VIII and all the reactions were minor. Among 81 patients who were tested for inhibitor formation, 16 had developed inhibitor to factor VIII. However, in nine of the 16 patients with inhibitor formation, inhibitor levels fell or disappeared altogether despite continued treatment with recombinant factor VIII.

Evaluation, Pediatric diseases, Drug therapy, Hemophilia, Blood coagulation factor VIII, Factor VIII (Blood coagulation), Hemophilia in children

---

AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs

Article Abstract:

The occurrence of AIDS-associated non-Hodgkin's lymphoma (AIDS-NHL) in hemophiliacs may be increasing in the later stages of AIDS diagnoses and may be linked with longer periods of immunosuppression. Of 33 HIV-infected hemophiliacs, those with NHL as their second AIDS-related disease were older and had lower CD4 counts following longer phases of immunosupression compared to those with NHL as their first AIDS-related disease. Antiretroviral therapy was responsible for an increase in survival rate as well as the prolonged immunosupression.

Complications and side effects, Demographic aspects, Non-Hodgkin's lymphomas, AIDS (Disease)

---

Similar abstracts:

• Abstracts: Pure red cell aplasia caused by D-penicillamine treatment of rheumatoid arthritis. Fatal aplastic anaemia and liver toxicity caused by D-penicillamine treatment of rheumatoid arthritis
• Abstracts: Comparative evaluation of clindamycin versus clindamycin plus tobramycin in the treatment of acute pelvic inflammatory disease
• Abstracts: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury
• Abstracts: Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination in the detection of asymptomatic nasopharyngeal carcinoma
• Abstracts: Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. The exclusion of the elderly and women from clinical trials in acute myocardial infarction

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.